Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
Balance Sheet
Inspect the capital base behind the business.
Assets
$692.29M
FY 2025 · Annual
Liabilities
$1.05B
FY 2025 · Annual
Equity
-$356.46M
FY 2025 · Annual
Balance Sheet
Metric | FY2025 Dec 2025 |
|---|---|
| Cash & Equivalents | 160.27M |
| Short-term Investments | 385.79M |
| Net Receivables | 2.73M |
| Inventory | 0 |
| Other Current Assets | 1.23M |
| Total Current Assets | 557.54M |
| Property, Plant & Equipment (Net) | 12.42M |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Long-term Investments | 106.67M |
| Tax Assets | 0 |
| Other Non-current Assets | 15.67M |
| Total Non-current Assets | 134.76M |
| Total Assets | 692.29M |
| Account Payables | 7.53M |
| Short-term Debt | 0 |
| Tax Payables | 0 |
| Deferred Revenue | 0 |
| Other Current Liabilities | 9.97M |
| Total Current Liabilities | 46.41M |
| Long-term Debt | 0 |
| Deferred Tax Liabilities | 0 |
| Deferred Revenue (Non-current) | 0 |
| Other Non-current Liabilities | 992.63M |
| Total Non-current Liabilities | 1B |
| Total Liabilities | 1.05B |
| Common Stock | 0 |
| Retained Earnings | (368.67M) |
| Accumulated OCI | 229K |
| Other Stockholders Equity | 0 |
| Minority Interest | 0 |
| Total Equity | (356.46M) |
| Total Debt | 10.75M |
| Net Debt | (149.51M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $130.3M |
| Short-term Investments | $786.4M |
| Other Current | $12.4M |
| Total Current Assets | $929.2M |
| PP&E (Net) | $11.7M |
| Other Non-current | $270.6M |
| Total Non-current Assets | $282.2M |
| Total Assets | $1.2B |
Analysis
Selected assets total $1.2B for Latest. The largest visible component is Short-term Investments at $786.4M, about 64.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
How much cash does KLRA have?
Kailera Therapeutics, Inc. (KLRA) reported $160.27M in cash and equivalents in fiscal 2025.
How much debt does KLRA carry?
Kailera Therapeutics, Inc. (KLRA) reported $10.75M of total debt, with net debt of -$149.51M.
Continue the stock analysis
Jump to another research area for this company.